リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain.

OBATA Shumpei 90814848 0000-0001-6120-2392 ICHIYAMA Yusuke 10749021 0000-0002-9134-9886 MATSUMOTO Riko 0000-0002-9650-9535 KAKINOKI Masashi 80531516 SAISHIN Yoshitsugu 30379193 0000-0001-9645-3837 YANAGI Takahide 70418755 MARUO Yoshihiro 80314160 OHJI Masahito 90252650 滋賀医科大学

2021.12.10

概要

Purpose:
To evaluate the short-term effect on body weight (BW) gain after intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).
Methods:
This was a retrospective 1:1 matched case-control study. Infants with ROP treated by IVB or photocoagulation (PC) at Shiga University of Medical Science Hospital between April 2010 and December 2019 were included in the study. To match BWs at treatment between the IVB and PC groups, 1:1 matching for BWs at treatment within 100 g was performed. The BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week) were compared between the IVB and PC groups.
Results:
Following 1:1 matching, 13 infants in both groups were enrolled in the analysis. The weekly BW gain for the first post-treatment week was significantly lower in the IVB group compared with the PC group (86 g vs. 145 g; P = 0.046), whereas the weekly BW gains for the pre-treatment week (173 g vs. 159 g; P = 0.71) and the second post-treatment week (154 g vs. 152 g; P = 0.73) were comparable between the two groups. The short-term inhibitive effect of IVB on BW gain was particularly observed in infants weighing less than 1500 g at treatment (<1500 g: 47 g vs. ≥1500 g: 132 g; P = 0.03).
Conclusion:
IVB could have a short-term inhibitive effect on BW gain in infants with ROP, and this effect is more likely to occur in infants with a lower BW at the time of treatment.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1.

Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk

and implications for control. Early Hum Dev. 2008; 84(2):77–82. Epub 2008/02/01. https://doi.org/10.

1016/j.earlhumdev.2007.11.009 PMID: 18234457.

2.

Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, et al. Progression of myopia and high

myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology. 2008; 115(6):1058–64 e1. Epub 2008/04/22. https://doi.org/10.1016/j.ophtha.2007.07.028

PMID: 18423871.

3.

Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, et al. Progression of myopia and high

myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J

AAPOS. 2013; 17(2):124–8. Epub 2013/04/30. https://doi.org/10.1016/j.jaapos.2012.10.025 PMID:

23622444; PubMed Central PMCID: PMC3725578.

4.

McLoone E, O’Keefe M, McLoone S, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11

years. J Pediatr Ophthalmol Strabismus. 2007; 44(3):170–3. Epub 2007/06/05. https://doi.org/10.3928/

0191-3913-20070301-10 PMID: 17542439.

5.

Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment

of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized

trial. Arch Ophthalmol. 2003; 121(12):1684–94. https://doi.org/10.1001/archopht.121.12.1684 PMID:

14662586.

6.

Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC. Efficacy of intravitreal bevacizumab for stage

3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603–15. https://doi.org/10.1056/

NEJMoa1007374 PMID: 21323540; PubMed Central PMCID: PMC3119530.

7.

Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes

following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical

trial. JAMA Ophthalmol. 2014; 132(11):1327–33. https://doi.org/10.1001/jamaophthalmol.2014.2772

PMID: 25103848.

8.

Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl EM, Wackernagel W, et al. A Systematic

Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for

the Treatment of Retinopathy of Prematurity. PLoS One. 2015; 10(6):e0129383. Epub 2015/06/18.

PLOS ONE | https://doi.org/10.1371/journal.pone.0261095 December 10, 2021

8/9

PLOS ONE

Effect of IVB for ROP on weight gain

https://doi.org/10.1371/journal.pone.0129383 PMID: 26083024; PubMed Central PMCID:

PMC4470662.

9.

Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J

Ophthalmol. 2012; 153(2):327–33 e1. https://doi.org/10.1016/j.ajo.2011.07.005 PMID: 21930258.

10.

Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018; 256(3):479–87. https://doi.org/10.1007/s00417-0173878-4 PMID: 29290015.

11.

Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and

after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol.

2016; 254(1):31–6. https://doi.org/10.1007/s00417-015-2996-0 PMID: 25851862.

12.

Ichiyama Y, Obata S, Saishin Y, Sawada O, Kakinoki M, Sawada T, et al. The systemic antiangiogenic

effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity. FASEB J. 2021;

35(3):e21390. Epub 2021/02/11. https://doi.org/10.1096/fj.202002414R PMID: 33566381.

13.

Kennedy KA, Mintz-Hittner HA, Group B-RC. Medical and developmental outcomes of bevacizumab

versus laser for retinopathy of prematurity. J AAPOS. 2018; 22(1):61–5 e1. https://doi.org/10.1016/j.

jaapos.2017.10.006 PMID: 29223789; PubMed Central PMCID: PMC5826862.

14.

Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab

and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol

Vis Sci. 2015; 56(2):956–61. https://doi.org/10.1167/iovs.14-15842 PMID: 25613938.

15.

Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; 137(4).

https://doi.org/10.1542/peds.2015-3218 PMID: 27244705.

16.

Homan GJ. Failure to Thrive: A Practical Guide. Am Fam Physician. 2016; 94(4):295–9. Epub 2016/08/

23. PMID: 27548594.

17.

Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013; 13:59. Epub 2013/04/23. https://doi.org/10.1186/1471-2431-13-59

PMID: 23601190; PubMed Central PMCID: PMC3637477.

18.

Tang F, LeBlanc ME, Wang W, Liang D, Chen P, Chou TH, et al. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis. 2019; 22(3):369–82. Epub 2019/01/16.

https://doi.org/10.1007/s10456-019-09662-4 PMID: 30644010; PubMed Central PMCID:

PMC6626703.

19.

Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Assessment of

Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.

JAMA Ophthalmol. 2017; 135(6):654–6. https://doi.org/10.1001/jamaophthalmol.2017.1055 PMID:

28448664; PubMed Central PMCID: PMC5521814.

20.

Crouch ER, Kraker RT, Wallace DK, Holmes JM, Repka MX, Collinge JE, et al. Secondary 12-Month

Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. JAMA

Ophthalmol. 2019. https://doi.org/10.1001/jamaophthalmol.2019.4488 PMID: 31697304.

21.

Kaushal M, Razak A, Patel W, Pullattayil AK, Kaushal A. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol.

2020. Epub 2020/12/10. https://doi.org/10.1038/s41372-020-00884-9 PMID: 33293666.

22.

Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity.

PLoS One. 2020; 15(3):e0230678. Epub 2020/03/21. https://doi.org/10.1371/journal.pone.0230678

PMID: 32196539; PubMed Central PMCID: PMC7083318.

23.

Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental Outcomes in Infants with

Retinopathy of Prematurity and Bevacizumab Treatment. PLoS One. 2016; 11(1):e0148019. https://

doi.org/10.1371/journal.pone.0148019 PMID: 26815000; PubMed Central PMCID: PMC4729687.

24.

Fan Y-Y, Huang Y-S, Huang C-Y, Hsu J-F, Shih C-P, Hwang Y-S, et al. Neurodevelopmental Outcomes

after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity. Ophthalmology. 2019. https://

doi.org/10.1016/j.ophtha.2019.03.048 PMID: 30954553

PLOS ONE | https://doi.org/10.1371/journal.pone.0261095 December 10, 2021

9/9

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る